Bone Replacement Products Market– Effective Solution for Bone Problems
The global bone replacement products market was valued at US$ 31.7 billion in 2016 and is expected to witness a robust CAGR of 4.4% over the forecast period (2017 - 2025).
Ask for detailed Sample of the Research Report @ www.coherentmarketinsights.com/insight/request-sample/1049
*The Sample consists of Table of Content, Research framework of the actual report & research methodology adopted for it
The bone replacement products market is expected to propel in Europe with the rising number of replacement procedures and readmissions. According to the European Commission, 2015, around 800,000 hip procedures were carried out every year in Europe, costing around US$ 1.5 billion. Furthermore, an estimated 20% of implants fail within 20 years, requiring corrective surgery costing an additional EUR 2.3 billion a year. Some of the major players operating in the bone replacement products market include Zimmer Biomet Holdings, Inc., B. Braun Melsungen AG, Stryker Corporation, Smith & Nephew Plc, United Orthopedic Corporation, Depuy Synthes, Medtronic Plc., Japan Medical Dynamic Marketing, Inc., JRI Orthopedics, Exactech, Inc., and Mathys.
Osteoporosis is characterized by low bone mineral density (BMD) and deterioration of bone tissues, leading to increased risk of developing traumatic bone fractures. The global incidence of osteoarthritis is expected to escalate, owing to increasing obesity and ageing population, in turn increasing demand for bone replacement products. According to the World Health Organization (WHO), 2013, around 28.2% of the global population above 60 years of age, suffered from osteoarthritis with an estimated 80% recorded with mobility handicaps. The market is expected to gain significant traction in North America, owing to the government initiatives to improve quality of life and reduce burden of people with musculoskeletal conditions. For instance, in 2014, the United States Bone and Joint Initiative (USBJI), an international collaborative movement sanctioned by the United Nations/World Health Organization, which helps increase awareness about the bone and joint health and disease prevention. However, increasing adoption of conservative medical therapies and non-operative methods such as anti-inflammatory medications for the treatment of musculoskeletal conditions are the factors restraining the growth of bone replacement products market.
To know more about the Global Bone Replacement Products Market, click the link below: www.coherentmarketinsights.com/market-insight/bone-replac...
Bone replacement products are required to fill the gap or replace the entire section following an accident or after tumor removal, which includes the implants made from metal, ceramic, plastic, and combination of materials. Bone replacement products are widely used when bone grafting is not possible. Moreover, improved mobility, improved quality of life, and cost-effectiveness of bone replacement procedures are major advantages offered by the bone replacement products as compared to non-operative treatments.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Visit our news Website: www.coherentchronicle.com
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bone Replacement Products Market– Effective Solution for Bone Problems here
News-ID: 984771 • Views: 202
More Releases from CMI - Market Research Reports
Multiplexed Diagnostic Market Driven By Innovation and Development of Technology
Mercodia has launched the AKURIO Islet Hormone multiplex assay with the collaboration of Quansys Bioscience in October 2017. This assay is designed to assess four different hormones in pancreatic study, which include glucagon, insulin, C-peptide, and proinsulin. AKURIO Islet Hormone multiplex assay provides high data accuracy with reliable speed. Moreover, Bruker has received CE-IVD marking for its Fungiplex Candida diagnostic assay in October 2017. Fungiplex Candida is based on real-time
U.S. Influenza Vaccines Market– Prevention of Virus through Vaccination Aids i …
The government agencies in the U.S. are focusing on collaborations in order to increase the supply of influenza vaccines. For instance, the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), and the National Institutes of Health (NIH) have partnered with the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to support the advanced development of new and better influenza
Radiology Information System (RIS) Market: Market Competitive Situation and Tren …
North America is projected to witness high share in the radiology information system market, owing to the well-established healthcare infrastructure and early adoption of the advancement in the medical and healthcare industry in the U.S. Furthermore, Asia Pacific region is emerging region in radiology information system market, owing to the increasing investments on healthcare facilities and increasing demand for diagnosis and treatment of chronic disease. For instance, according to the
Immuno-Oncology Drugs Market is expected to witness a robust CAGR of 14.9% over …
The Global Immuno-oncology Drugs Market by Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine-Based Immunotherapy, Cancer Vaccines, and CAR-T Cell Therapy), by Cancer Type (Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Gastric Cancers, Glioblastoma, and Head & Neck Cancers), and by Region was valued at US$ 43,084.5 million in 2016 and is projected to exhibit a CAGR of 14.9%